financetom
Business
financetom
/
Business
/
Essent Group Q1 Earnings Fall, Revenue Rises
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Essent Group Q1 Earnings Fall, Revenue Rises
May 26, 2025 4:56 AM

06:57 AM EDT, 05/09/2025 (MT Newswires) -- Essent Group ( ESNT ) reported Q1 earnings Friday of $1.69 per diluted share, down from $1.70 a year earlier.

Analysts polled by FactSet expected $1.66.

Revenue for the quarter ended March 31 was $317.6 million, up from $298.4 million a year earlier.

Four analysts surveyed by FactSet expected $310.4 million.

The company declared a quarterly dividend of $0.31 per share, payable June 10 to shareholders of record May 30.

Essent ( ESNT ) shares were up 1.3% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Summit Therapeutics Insider Bought Shares Worth $5,984,756, According to a Recent SEC Filing
Summit Therapeutics Insider Bought Shares Worth $5,984,756, According to a Recent SEC Filing
Sep 12, 2025
03:27 AM EDT, 09/12/2025 (MT Newswires) -- Mahkam Zanganeh, 10% Owner, Director, Co-Chief Executive Officer, on September 10, 2025, executed a purchase for 338,394 shares in Summit Therapeutics ( SMMT ) for $5,984,756. Following the Form 4 filing with the SEC, Zanganeh has control over a total of 591,831,532 common shares of the company, with 31,000 shares held directly and...
Lazard Insider Sold Shares Worth $4,240,260, According to a Recent SEC Filing
Lazard Insider Sold Shares Worth $4,240,260, According to a Recent SEC Filing
Sep 12, 2025
03:29 AM EDT, 09/12/2025 (MT Newswires) -- Evan L Russo, Chief Executive Officer of Asset Management, on September 09, 2025, sold 75,000 shares in Lazard ( LAZ ) for $4,240,260. Following the Form 4 filing with the SEC, Russo has control over a total of 227,915 common shares of the company, with 227,915 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1311370/000171748925000003/xslF345X05/wk-form4_1757633247.xml ...
Summit Therapeutics Insider Bought Shares Worth $5,984,756, According to a Recent SEC Filing
Summit Therapeutics Insider Bought Shares Worth $5,984,756, According to a Recent SEC Filing
Sep 12, 2025
03:28 AM EDT, 09/12/2025 (MT Newswires) -- Robert W Duggan, 10% Owner, Director, Co-Chief Executive Officer, on September 10, 2025, executed a purchase for 338,394 shares in Summit Therapeutics ( SMMT ) for $5,984,756. Following the Form 4 filing with the SEC, Duggan has control over a total of 591,831,532 common shares of the company, with 556,093,090 shares held directly...
United Therapeutics Insider Sold Shares Worth $3,183,777, According to a Recent SEC Filing
United Therapeutics Insider Sold Shares Worth $3,183,777, According to a Recent SEC Filing
Sep 12, 2025
03:25 AM EDT, 09/12/2025 (MT Newswires) -- Martine A Rothblatt, Director, Chairperson & Chief Executive Officer, on September 10, 2025, sold 8,000 shares in United Therapeutics ( UTHR ) for $3,183,777. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 644,489 common shares of the company, with 130 shares held directly and 644,359 controlled...
Copyright 2023-2026 - www.financetom.com All Rights Reserved